Navigation Links
Cadaver tissue fails nearly 25 percent of the time in young ACL reconstructions
Date:7/9/2008

ORLANDO, Florida With an estimated 80,000 Anterior Cruciate Ligament (ACL) tears happening each year in the United States (Source: American Journal of Sports Medicine 2006 ; 9:1512-1532), including recently to famed golfer, Tiger Woods, choosing the best replacement ligament for surgery is one key to success. A study released today at the 2008 American Orthopaedic Society for Sports Medicine's Annual Meeting at the JW Marriott Orlando Grande Lakes, found that with a failure rate of almost 24 percent, the use of cadaver replacement ligaments may not be the best choice for young, athletic patients.

"Choosing a replacement ligament, whether it comes from a cadaver or the patient's own tissue is a decision that must be made by the surgeon and patient," said co-author Kurre Luber, MD, orthopedic surgery fellow at Mississippi Sports Medicine and Orthopaedic Center. "This study found a very high failure rate in patients 40 years and younger with high activity levels in ACL-dependent sports like tennis, basketball, soccer and downhill skiing. Certainly, it would be nave to think that only the graft selection led to these failures, we also need to look at surgical technique (single versus double bundle). Better outcome measures also need to be developed. However, this study definitely raises questions about the validity of using cadaver tissue in this patient subgroup."

The ACL is one of the major stabilizing ligaments of the knee. Located in the center of the knee joint, it runs from the thigh bone to the shin bone through the center of the knee. Typically, tearing the ACL occurs with a sudden direction change. To repair a torn ACL, a surgeon replaces the damaged ligament with a new one, either from a cadaver or the patient's own body. Typically, either the patellar-tendon bone or the hamstring tendons is used.

In the study, 64 patients, 40 years old or younger with high activity levels who had ACL reconstruction with a cadaver replacement ligament, were followed for a minimum of two years. ACL reconstruction failure was defined as requiring a second reconstruction due to injury or graft failure or poor scores on a combination of orthopaedic outcome measure tests. The study found that 15 (23.4 percent) of the 64 patients' ACL reconstructions failed as defined by the study.

"This failure rate in this young, active population is exceedingly high when compared to a previous study that looked at failure rates of cadaver replacement ligament in patients older than 40," said corresponding author Dr. Gene Barrett. "The older group's failure rate was 2.4 percent. So while there are obvious benefits of using the cadaver ligament, like avoiding a second surgical site on the patient, a quicker return to work and less postoperative pain, for a young patient who is very active, it may not be the right choice."


'/>"/>

Contact: Lisa Weisenberger
lisa@aossm.org
847-292-4900
American Orthopaedic Society for Sports Medicine
Source:Eurekalert

Related medicine news :

1. Donate Life America Dispels Myths About Organ & Tissue Donation Among Hispanics During National Hispanic Heritage Month
2. USC researcher identifies stem cells in tendons that regenerate tissue in animal model
3. Stem cells derived from adult testes produce wide range of tissue types
4. Stem Cells From Testes Produce Wide Range of Tissue Types
5. Tissue-Growth Gene Tied to Scleroderma
6. Two Million Californians Say Yes! to Organ and Tissue Donation
7. Starion Instruments Launches Next-Generation Tissue Ligating Shears at the American College of Surgeons Clinical Congress
8. Osteotech Completes Tissue Supply Agreement With LifeNet Health
9. Normal tissue not spared in new forms of breast cancer radiotherapy
10. Tissue Genesis Signs Exclusive Distribution and License Agreement with SpineSmith
11. Studies Investigate Diagnostic Performance and Reproducibility of Pathwork Diagnostics Tissue of Origin Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... (PRWEB) , ... February 06, 2016 , ... ... phases of eating disorder treatment helps to reduce the frequency and level of ... the Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks ...
(Date:2/5/2016)... Toronto, Ontario (PRWEB) , ... February 05, 2016 ... ... today announced the availability of the company's lighter, sleeker next generation LYNX VR ... assembly plant. , Improvements in design and manufacturing not only reduce the ...
(Date:2/5/2016)... ... ... The event is being held on April 7, 2016 from 5:30 p.m. ... Parkinson’s will fund nearly $100,000 for research for the care and cure of Parkinson’s ... is the architect of this informative event to raise awareness and funds for Parkinson’s. ...
(Date:2/5/2016)... ... February 05, 2016 , ... Looking for a last-minute Valentine’s ... the tips of your toes. Foot massage, whether administered by a professional masseuse or ... relaxation. The American Board of Multiple Specialties in Podiatry (ABMSP) has taken ...
(Date:2/5/2016)... Florida (PRWEB) , ... February 05, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – is poised to once again host, Swirl, A Wine Tasting Event at ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... Feb. 5, 2016 Amgen (NASDAQ: AMGN ) ... Global Healthcare Conference at 9:15 a.m. ET on Wednesday, Feb. ... David W. Meline , executive vice president and chief ... audio of the presentation can be accessed from the Events ... replay of the webcast will also be available on Amgen,s ...
(Date:2/5/2016)... 2016  ivWatch, a medical devices company, is one of ... by Governor Terry McAuliffe,s office. ivWatch will be ... at an event to be held at the Science Museum ... professionals and business that have made significant contributions to science. ... http://photos.prnewswire.com/prnh/20160205/330117LOGO ...
(Date:2/5/2016)... Feb. 5, 2016  Aralez Pharmaceuticals Inc. ("Aralez") today ... Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval ... of Tribute. The combined company will operate under Aralez ... operations in Canada , ... . Under the terms of the Agreement and ...
Breaking Medicine Technology: